Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors

John Ramage, Boris G. Naraev, Thorvardur R. Halfdanarson*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

55 Citations (Scopus)


177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is now approved for patients with advanced gastroenteropancreatic neuroendocrine tumors (NET), and it is therefore important to understand the efficacy and safety of PRRT in this patient population. PRRT efficacy and safety outcomes have frequently been summarized for patient populations with gastroenteropancreatic NET, but not specifically in patients with pancreatic NET (panNET). The pivotal phase 3 trial of 177Lu-DOTATATE PRRT in NET was restricted to patients with a midgut primary site. No phase 3 trial data on PRRT treatment outcomes are currently available for the panNET patient population. This review presents the available evidence for panNET treatment outcomes with PRRT and demonstrates that the available data favor PRRT as a modality for this NET primary site. However, several other therapies for advanced panNET are currently available, and the sequencing and combination of PRRT with these other therapies is set to become the big challenge for the future of panNET management. Patient, tumor, and logistical factors (tumor burden, expression of somatostatin receptors, availability of PRRT, patient preferences, and concerns over long-term toxicity) need to be taken into consideration when selecting therapy.

Original languageEnglish
Pages (from-to)236-248
Number of pages13
JournalSeminars in Oncology
Issue number4
Publication statusPublished - Aug 2018


  • Neuroendocrine tumors
  • Pancreas
  • Pancreatic
  • Peptide receptor radionuclide therapy


Dive into the research topics of 'Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this